Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism

Shannon Rose1, Sirish C. Bennuri1, Jakeira E. Davis1, Rebecca Wynne1, John C. Slattery1, Marie Tippett1, Leanna Delhey1, Stephan Melnyk1, Stephen G. Kahler1, Derrick F. MacFabe2 and Richard E. Frye1,3

Abstract
Butyrate (BT) is a ubiquitous short-chain fatty acid (SCFA) principally derived from the enteric microbiome. BT positively modulates mitochondrial function, including enhancing oxidative phosphorylation and beta-oxidation and has been proposed as a neuroprotectant. BT and other SCFAs have also been associated with autism spectrum disorders (ASD), a condition associated with mitochondrial dysfunction. We have developed a lymphoblastoid cell line (LCL) model of ASD, with a subset of LCLs demonstrating mitochondrial dysfunction (AD-A) and another subset of LCLs demonstrating normal mitochondrial function (AD-N). Given the positive modulation of BT on mitochondrial function, we hypothesized that BT would have a preferential positive effect on AD-A LCLs. To this end, we measured mitochondrial function in ASD and age-matched control (CNT) LCLs, all derived from boys, following 24 and 48 h exposure to BT (0, 0.1, 0.5, and 1 mM) both with and without in vitro increase in reactive oxygen species (ROS). We also examined the expression of key genes involved in cellular and mitochondrial response to stress. In CNT LCLs, respiratory parameters linked to adenosine triphosphate (ATP) production were attenuated by 1 mM BT. In contrast, BT significantly increased respiratory parameters linked to ATP production in AD-A LCLs but not in AD-N LCLs. In the context of ROS exposure, BT increased respiratory parameters linked to ATP production for all groups. BT was found to modulate individual LCL mitochondrial respiration to a common set-point, with this set-point slightly higher for the AD-A LCLs as compared to the other groups. The highest concentration of BT (1 mM) increased the expression of genes involved in mitochondrial fission (PINK1, DRP1, FIS1) and physiological stress (UCP2, mTOR, HIF1α, PGC1α) as well as genes thought to be linked to cognition and behavior (CREB1, CamKinase II). These data show that the enteric microbiome-derived SCFA BT modulates mitochondrial activity, with this modulation dependent on concentration, microenvironment redox state, and the underlying mitochondrial function of the cell. In general, these data suggest that BT can enhance mitochondrial function in the context of physiological stress and/or mitochondrial dysfunction, and may be an important metabolite that can help rescue energy metabolism during disease states. Thus, insight into this metabolic modulator may have wide applications for both health and disease since BT has been implicated in a wide variety of conditions including ASD. However, future clinical studies in humans are needed to help define the practical implications of these physiological findings.

Introduction
The human body houses a diverse ecosystem of microbes collectively referred to as the human microbiome. Interestingly, it is believed that there may be more microbial cells than human cells in the human body with perhaps over 10–100 times more microbial genes than
human genes\textsuperscript{1–3}. The enteric (gut) microbiota is an area of great interest since it accounts for approximately 99% of the human microbiome\textsuperscript{4} and modulates the immune system\textsuperscript{5}, metabolism\textsuperscript{6}, receptor physiology\textsuperscript{7}, and gene expression\textsuperscript{8,9}. Alterations in the enteric microbiome, dynamically throughout the lifecycle, but particularly in early life, have been implicated in health and disease, including psychiatric disorders such as depression and anxiety\textsuperscript{10}, gastrointestinal (GI) disorders\textsuperscript{11}, inflammatory airway disease\textsuperscript{12}, diabetes\textsuperscript{13–15}, obesity\textsuperscript{16,17}, atopic disease\textsuperscript{5}, neurodegenerative conditions\textsuperscript{18}, and early brain development and behavior\textsuperscript{19–21}.

The microbiome modulates host physiology through the production of metabolic mediators, including lipopolysaccharides, peptidoglycans, short-chain fatty acids (SCFA), neurotransmitters, and gaseous molecules\textsuperscript{22–24}. SCFAs, such as propionic acid (PPA), butyric acid (BT), and acetic acid, are produced as a consequence of fermenting carbohydrates and some proteins\textsuperscript{18,25,26} and modulate host physiology\textsuperscript{26–28}. For example, PPA can modulate cell signaling\textsuperscript{29,30}, cell–cell interactions\textsuperscript{31}, gene expression\textsuperscript{32,33}, immune function\textsuperscript{34}, neurotransmitter synthesis and release\textsuperscript{35}, and mitochondrial\textsuperscript{36} and lipid\textsuperscript{37} metabolism. PPA has positive health effects, having anti-obesity\textsuperscript{37,38}, anti-inflammatory\textsuperscript{27,39} and anti-bacterial effects\textsuperscript{35}, as well as lowering cholesterol\textsuperscript{27}. Likewise, BT is a substrate for energy production, a regulator of energy metabolism\textsuperscript{40}, a histone deacetylase inhibitor\textsuperscript{41}, a modulator of immune function\textsuperscript{42}, and a modulator of local gut physiology\textsuperscript{43}. BT has positive effects in biological models of several important human diseases, including diabetes\textsuperscript{43,44}, neurodegenerative disorders\textsuperscript{18,45}, leukemia\textsuperscript{46}, lymphoma\textsuperscript{47}, and colorectal\textsuperscript{48,49}, breast\textsuperscript{50,51}, and pancreatic\textsuperscript{52} cancers.

Autism spectrum disorder (ASD) affects ~2% of children in the United States. The cause(s) of ASD are still unknown but evidence for a simple genetic defect is lacking\textsuperscript{53}. The etiology of ASD likely involves environmental factors, which affect broad cell signaling, metabolic, immune, and epigenetic processes in genetically sensitive individuals\textsuperscript{53,54}. Of particular note, ASD is associated with physiological disturbances including abnormal redox and mitochondrial metabolism. In fact, between 5% and 80% of children with ASD manifest mitochondrial dysfunction, with many demonstrating novel types of mitochondrial dysfunction rather than classic mitochondrial disease\textsuperscript{37,55,56}. This is in comparison to the general population where mitochondrial disease is believed to effect <0.1% of the population\textsuperscript{57}.

ASD is associated with GI and microbiome disturbances, potentially caused by an alteration in the dietary diversity, environmental exposures, C-section, antibiotics, formula feeding, and early hospitalization\textsuperscript{2,20,36}. The enteric microbiome is uniquely positioned as a contributory etiological environmental factor for ASD\textsuperscript{2,20,21,36} and, as discussed in our recent review, there appears to be a close association between microbiome disturbances, mitochondrial dysfunction, and ASD\textsuperscript{20}. We believe the microbiome is important to the understanding of ASD in some children since Clostridia spp, a major SCFA producer, has been repeatedly found to be over-represented in the ASD gut\textsuperscript{38,59}.

We have previously demonstrated that PPA may link the microbiome, mitochondria, and ASD. Brief pulsed PPA infusions into an adult rat cerebral ventricles produces behaviors and physiological changes associated with ASD\textsuperscript{25,26,60}, while rats systemically exposed to PPA pre- and post-natally develop ASD-like behaviors in a sexually dimorphic manner, recapitulating the neurodevelopmental aspects of ASD\textsuperscript{61–63}. Additionally, the metabolic changes found in ASD patients have been replicated in the PPA rodent model. Of note, a unique pattern of biomarkers of mitochondrial dysfunction found in the PPA rodent model is found in 17–24% of the children with ASD\textsuperscript{37,64}. Furthermore, PPA modulates mitochondrial respiration in a concentration- and exposure time-dependent manner in lymphoblastoid cell lines (LCLs) derived from children with ASD\textsuperscript{65}.

Another major SCFA produced by the gut microbiome, BT, also has connections to ASD and mitochondrial function. BT rescues behavior\textsuperscript{66,67} and brain pathophysiology\textsuperscript{67} and pathology\textsuperscript{66,68} in animal models of ASD. BT supports mitochondrial function, stimulating oxidative phosphorylation and fatty acid oxidation\textsuperscript{69}, upregulates physiological stress pathways\textsuperscript{69–71}, and is critical for colonocyte mitochondrial function in germ-free mice\textsuperscript{40}. Animal models have suggested that BT, given through the GI tract or injected intraperitoneally, may be therapeutic in neurologic and psychiatric conditions including depression\textsuperscript{72}, dementia\textsuperscript{73–75}, traumatic brain injury\textsuperscript{76}, and motoneuron disease\textsuperscript{77}. However, early post-natal exposure to BT may contribute to colitis\textsuperscript{78}.

Given the connection between ASD and mitochondrial function and given that BT is a fermentation product of ASD-associated bacteria\textsuperscript{76}, we believe that BT is an important SCFA to study. We applied our LCL model of mitochondrial dysfunction in ASD to help understand the role of BT in modulating mitochondrial function. We have developed a cell line model of ASD in which LCLs from children with autistic disorder (AD) are classified into two groups: those with normal mitochondrial function (AD-N) and those with atypical mitochondrial function (AD-A)\textsuperscript{79–81}. The AD-A LCLs have respiratory rates approximately twice that of the control (CNT) and AD-N LCLs and are very sensitive to in vitro increases in reactive oxygen species (ROS)\textsuperscript{79–81}. Given the positive modulatory effects of BT on mitochondrial function, we hypothesized that BT would improve mitochondrial
function in AD-A LCLs while having little effect on the CNT and AD-N LCLs. Furthermore, given the ability of BT to increase the expression of cellular pathways involved in cellular stress, we anticipated that this effect would extend to improving mitochondrial function in the AD-N and CNT LCLs when they are subjected to increased physiological stress.

Thus, we measured the effects of BT on mitochondrial function and determined whether these effects are dependent on concentration, exposure duration, the microenvironment redox state, or the underlying mitochondrial physiology (i.e., LCL group: AD-A, AD-N, CNT). In addition to studying how these factors modulated mitochondrial function on average in the overall groups, we examined the effect of BT on modulating mitochondrial function on an individual cell line basis. Furthermore, we measured the ability of BT to modulate the expression of key genes linked to mitochondrial and physiological stress as well as genes linked to cognition and behavior in ASD.

**Methods**

**LCLs and culture conditions**

ASD LCLs were derived from white boys diagnosed with AD chosen from pedigrees with at least other 1 affected male sibling (i.e., multiplex family) [mean (SD) age 8.5 (3.0) years]. These LCLs were obtained from the Autism Genetic Resource Exchange (Los Angeles, CA, USA) and the National Institutes of Mental Health (Bethesda, MD, USA) center for collaborative genomic studies on mental disorders. These biorepositories use a gold-standard examination to diagnose AD, either the autism diagnostic observation schedule (ADOS) or the autism diagnostic interview revised (ADI-R).

In our previous studies, these LCLs were categorized into two different types of AD LCLs; ones with atypical mitochondrial respiration (AD-A) and those with typical respiration (AD-N). These metabolic groupings have been shown to be consistent and repeatable in our previous studies. Twelve pairs of AD-N and AD-A LCLs were run with an age-matched male CNT LCL. The sample size chosen was based on our previous studies. CNT LCLs were derived from healthy white male donors with no documented behavioral or neurological disorder [mean (SD) age 8.5 (2.8) years]. CNT LCLs were obtained from Coriell Cell Repository (Camden, NJ, USA).

Due to low availability of CNT LCLs which fit our criteria, a single CNT LCL was matched with two AD LCLs in one case and with three AD LCLs in another case (see Table 1). Also, five AD-A LCLs were matched twice with AD-N LCLs. This matching was done to control for variations in the measurement of mitochondrial function. On average, cells were studied at passage 12, with a maximum passage of 15. Genomic stability is very high at this low passage number. The cells were maintained in RPMI 1640 culture medium with 15% FBS and 1% penicillin/streptomycin.

### Table 1 Lymphoblastoid cell lines used in this study

| Controls | AD-N subgroup | AD-A subgroup |
|----------|---------------|---------------|
| Cell ID  | Source | Age (y) | Cell ID | Source | Age (y) | Cell ID | Source | Age (y) |
| GM09622  | Coriell | 7 | 02C10618 | NIMH | 7 | 03C14441 | NIMH | 7 |
| GM17255  | Coriell | 6 | 02C10054 | NIMH | 6 | 01C08594 | NIMH | 7 |
| GM15862  | Coriell | 11 | 04C26296 | NIMH | 10 | 03C16499 | NIMH | 11 |
| GM09659  | Coriell | 4 | 04C24363 | NIMH | 4 | 1393306 | AGRE | 3 |
| GM10153  | Coriell | 10 | 00C04757 | NIMH | 10 | 939303 | AGRE | 11 |
| GM11626  | Coriell | 13 | AU008404 | AGRE | 13 | 1165302 | AGRE | 13 |
| GM11973  | Coriell | 7 | 02C09650 | NIMH | 7 | 02C09713 | NIMH | 7 |
| GM18054  | Coriell | 5 | 03C15992 | NIMH | 5 | 01C08495 | NIMH | 4 |
| GM16007  | Coriell | 12 | 05C38988 | NIMH | 12 | 1165302 | AGRE | 13 |
| GM11599  | Coriell | 9 | AU038804 | AGRE | 8 | 03C14441 | NIMH | 7 |
| GM10153  | Coriell | 10 | AU1267302 | AGRE | 10 | 03C16499 | NIMH | 11 |
| GM10153  | Coriell | 10 | 03C17237 | NIMH | 10 | 939303 | AGRE | 11 |

Three types of cell lines were used with two types of autistic disorder cell lines which were characterized in our previous studies. All cell lines were derived from male participants.

Coriell Cell Repository (Camden, NJ, USA), NIMH National Institutes of Mental Health Biorepository (Bethesda, MD, USA), AGRE Autism Genetic Resource Exchange Biorepository (Los Angeles, CA, USA)
(Invitrogen, Grand Island, NY, USA) in a humidified incubator at 37 °C with 5% CO2.

Seahorse assay
A Seahorse Extracellular Flux (XF) 96 Analyzer (Seahorse Bioscience, Inc., North Billerica, MA, USA) measured the oxygen consumption rate (OCR), an indicator of mitochondrial respiration, in live intact LCLs in real-time. Each run (each line of Table 1) contained the three matched groups (CNT, AD-N, AD-A) on the same plate to control for experimental variation in the mitochondrial activity measurement. The assay (Fig. 1a), which has been described previously, provides measures of ATP-linked respiration, proton leak respiration, maximal respiratory capacity, and reserve capacity. In addition, the extracellular acidiﬁcation rate (ECAR), a reﬂection of lactate production, is also measured during the assay. From the ECAR, glycolytic rate and glycolytic reserve are calculated.

In addition, to obtain a measure of the relative utilization of oxidative vs. glycolytic pathways, two measures are calculated. The oxidative to glycolytic ratio is calculated as basal OCR divided by basal ECAR and the maximal oxidative capacity to glycolytic ratio is calculated as the maximal respiratory capacity divided by the maximal glycolytic rate.

Redox challenge
To determine the change in mitochondrial response to BT in the context of oxidative stress, LCLs were exposed to 0 µM or 10 µM of 2,3-dimethoxy-1,4-napthoquinone (DMNQ; Sigma-Aldrich, St. Louis, MO, USA) for 1 h at 37 °C in a non-CO2 incubator prior to the Seahorse assay, similar to our previous studies (See Fig. 1b). A 5-mg/mL DMNQ solution was diluted in DMEM XF assay media into a 10× stock and added to cells in an XF-PS plate.

Butyrate exposure
LCLs were cultured with one of the three BT concentrations (0.1, 0.5, and 1 mM) for 24 h or 48 h prior to the Seahorse assay or left untreated (0 mM) (Fig. 1b). These concentrations were chosen as standards in the field and simulate the concentrations in the colon but are below those known to induce apoptosis. In humans, BT concentration is highest in the cecum, where most anaerobic gut fermentation takes place (24.5 mM/kg), and lowest in the ileum (2.3 mM/kg). BT produced from the gut microbiome is absorbed primarily from the gut into the portal vein where its concentration is about 29 µM. The sodium butyrate used in this study was buffered with sodium bicarbonate in the culture medium to prevent changes in pH which could cause pH-dependent changes in the influx of BT.

Gene expression
Total RNA was isolated from 5 million LCLs using the RNeasy mini kit (Qiagen, Hilden, Germany) following manufacturer’s protocol. Complementary deoxyribonucleic acid (cDNA) synthesis (2 µg per 20 µL reaction mix) was performed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham Massachusetts, USA) following the manufacturer’s protocol.
Analytic approach

To analyze group effects, a mixed-model regression was conducted via SAS version 9.3 (Cary, NC, USA) ‘glimmix’ procedure. The mixed model allowed data from the matched samples on each Seahorse plate to be compared to one another. The mitochondrial parameters were response variables with a between-group effect (e.g., AD-N vs. AD-A vs. CNT) and within-group repeated factors of BT concentration, exposure duration, and ROS exposure as well as the interaction between these effects. For all models, random effects included the intercept. F-tests were used to evaluate significance. F-tests from the mixed models are presented in Supplementary Tables.

Planned post-hoc orthogonal contrasts, which are t-distributed, were used to examine significant group and interaction effects. These results are reported as p-values in the graphs. When the effect of BT concentration was significant, the specific BT concentrations were compared to baseline (i.e., 0 BT) to determine if they were significantly higher or lower than the baseline. Data were normally distributed and variation was similar across the groups. Standard error bars are provided in graphs. Gene expression was analyzed similarly, although only two BT concentrations for 24 h exposure without DMNQ exposure were examined.

To examine whether the influence of BT on mitochondrial respiration was dependent on individual baseline variation in mitochondrial respiration, we used a curvilinear model with a second-order polynomial to model BT concentration as a continuous variable. Interactions with baseline mitochondrial respiration as well as interaction with exposure time and LCL group (CNT, AD-A, AD-N) were included in the model. To evaluate the influence of LCL group and the interaction of LCL group on the curve shape, the significance of the change in the log-likelihood of the model was assessed using a $\chi^2$ distribution. The model effects are reported in Table S3. Planned orthogonal contrasts were conducted to determine the differences among the LCL groups when the effects were significant. Goodness-of-fit of the models was assessed using $r^2$ and F-ratios. The models fit well to the data [ATP-linked respiration: $F(8405) = 137.8, p < 0.0001$, $r^2 = 0.63$, $r = 0.79$; proton leak respiration: $F(8405) = 36.3, p < 0.0001$, $r^2 = 0.40$, $r = 0.63$; maximum respiratory capacity: $F(13,400) = 76.7, p < 0.0001$, $r^2 = 0.60$, $r = 0.77$; reserve capacity: $F(13,400) = 52.01, p < 0.0001$, $r^2 = 0.41$, $r = 0.64$]. Resulting graphs display individual LCLs response to BT based on predicted curves using the model parameters and individual LCLs data. Curves are the average of the 24-h and 48-h exposures since these were not significantly different in the model.

Results

We examined three different aspects of the effect of BT. First, we analyzed the group differences between ASD and CNT groups with respect to the effect of BT and increased ROS exposure. Second, we examined how individual baseline mitochondrial function influences the effect of BT. Lastly, we studied the ability of BT to regulate the expression of the key genes.

Group differences of the effect of BT on ASD and CNT cell lines

We approach the comparison between CNT and ASD cell lines and the differences between the two types of ASD cell lines (AD-N, AD-A) in a systematic fashion. First, we examined the effect of BT on CNT LCLs in the absence of DMNQ exposure. Second, we examined the effect of DMNQ (i.e., increase in ROS) on CNT LCLs. We then used these findings from CNT LCLs as a baseline to compare the effect of BT on the two groups of ASD LCLs. We then examine the effect of ROS exposure (i.e., pretreatment with DMNQ) on ASD LCLs in reference to the CNT LCLs. Table S2 provides the F-values for the effect of the mixed model in this section. Results of individual comparisons are provided in the figures.

Group differences: the effect of BT on CNT cell lines

One millimolar BT reduced all the parameters of ATP production, including ATP-linked respiration, maximal respiratory capacity, and reserve capacity (Fig. 2a, c, d) but did not affect proton leak respiration (Fig. 2b). Likewise, 1 mM BT reduced glycolytic rate (Fig. 2e) and glycolytic capacity ratio (OCR/ECAR) (mean (SE) 24 h 0.37 (0.04) vs. 48 h 0.29 (0.04)) and maximal oxidative to glycolytic ratio (OCR/ECAR) were increased by 1 mM BT (Fig. 2g, h).

Although not shown in the figure, shorter BT exposure time (i.e., 24 h) was associated with a significantly higher oxidative to glycolytic ratio (OCR/ECAR) [mean (SE) 24 h 0.37 (0.04) vs. 48 h 0.29 (0.04)] and maximal oxidative to glycolytic capacity ratio (OCR/ECAR) [mean (SE) 24 h 0.59 (0.06) vs. 48 h 0.47 (0.06)]. No other parameters were affected by exposure time, so the figure represents an average of the two exposure times.
Group differences: the effect of ROS on CNT cell lines

Since the results for the 24 h and 48 h BT exposure are so similar, only the 24 h results are presented here. The result for the 48 h BT exposure can be found in the Supplementary Materials. DMNQ lowered the maximal respiratory capacity and reserve capacity (Fig. 3c, d) and increased proton leak respiration (Fig. 3b). The strong detrimental effect of 1 mM BT on ATP-linked respiration, maximal respiratory capacity, and reserve capacity noted in the previous section (i.e., without DMNQ) was not seen when the CNT LCLs were exposed to DMNQ, resulting in a DMNQ by BT concentration interactions. In fact, there was a slight increase in reserve capacity at 1 mM BT (Fig. 3d) with DMNQ exposure as compared to no DMNQ exposure.

DMNQ lowered the glycolytic rate and increased the glycolytic reserve (Fig. 3e, f). The significant drop in glycolytic rate found at 1 mM BT concentration without DMNQ exposure was not seen when the CNT LCLs were exposed to DMNQ, resulting in a DMNQ by BT concentration interaction. DMNQ increased the oxidative to glycolytic ratio (OCR/ECAR) and decreased the maximal oxidative to glycolytic capacity ratio (OCR/ECAR) (Fig. 3g, h). The increase in the maximal oxidative to glycolytic capacity ratio found at 1 mM in CNT LCLs without exposure to DMNQ was not seen with DMNQ exposure, resulting in a DMNQ by BT concentration interaction.

Group differences: ASD cell lines

Here, we compare the difference in mitochondrial respiration between the ASD and CNT LCLs. The graphs represent the difference from respiration of control LCLs. Since the results for the two exposure times are similar, only the results for the 24 h exposure are reported here and the results for the 48 h exposures are reported in the Supplementary Materials.

Group differences: the effect of 24 h BT exposure on ASD cell lines

BT exposure resulted in significant increases in the respiratory parameters linked to ATP production in the AD-A LCLs as compared to the other LCL groups, resulting in a BT concentration by group interaction for ATP-linked respiration, maximal respiratory capacity, and reserve capacity. ATP-linked respiration was higher than baseline for AD-A at 0.1 mM BT as compared to AD-N and at 1 mM BT as compared to CNT (Fig. 4a). Maximal respiratory capacity was higher than baseline for AD-A at 0.1 and 0.5 mM BT as compared to CNT and AD-N and at 1 mM BT as compared to CNT (Fig. 4c). Reserve capacity increased from baseline for AD-A at 0.1 and 0.5
mM BT as compared to CNT and AD-N, and at 1 mM BT as compared to CNT (Fig. 4d).

Glycolytic rate of AD-A was significantly higher than CNT LCLs (Fig. 4e). AD-N demonstrated a significantly lower glycolytic reserve as compared to AD-A (Fig. 4f). The oxidative to glycolytic ratio (OCR/ECAR) was significantly higher for AD-A as compared to AD-N and CNT (Fig. 4g). The maximal oxidative to glycolytic capacity ratio (OCR/ECAR) was significantly higher in AD-A as compared to AD-N and CNT (Fig. 4h).

**Group differences: the effect of oxidative stress on 24 h BT exposure on ASD cell lines**

Maximal respiratory capacity, reserve capacity, and proton leak respiration demonstrated BT concentration by group interactions. Some results paralleled the 24 h BT exposure without DMNQ. Maximal respiratory capacity was higher for AD-A at 1 mM BT as compared to CNT and AD-N (Fig. 5c). Reserve capacity was significantly higher for AD-A at 0.5 mM BT as compared to CNT and AD-N at 0.1 mM as compared to CNT (Fig. 5d). Proton leak respiration was significantly higher for AD-A at 1 mM BT as compared to CNT (Fig. 5b).

Glycolytic rate was significantly higher for AD-A as compared to CNT and AD-N (Fig. 5e). For glycolytic reserve, there was a group by BT concentration interaction due to AD-A being able to maintain glycolytic reserve with an exposure of 1 mM BT as compared to AD-N ($p < 0.01$) and CNT where glycolytic reserve was lost (Fig. 5f). Oxidative to glycolytic ratio (OCR/ECAR) was higher for AD-A as compared to AD-N and CNT (Fig. 5g). Maximal oxidative to glycolytic capacity ratio (OCR/ECAR) was significantly higher for AD-A as compared to AD-N (Fig. 5h).

**Individual differences: the effect of butyrate on variation in respiratory function**

The effect of BT on ATP-linked respiration was found to be curvilinear with the intercept different across LCL groups because the AD-A curve intercept was higher than the AD-N ($p < 0.0001$) and CNT ($p < 0.0001$) intercepts. Individual baseline ATP-linked respiration influenced the effect of BT on ATP-linked respiration (Fig. 6). BT regulated ATP-linked respiration such that ATP-linked respiration was modulated to a particular set-point regardless of the baseline ATP respiration. LCLs with baseline ATP-linked respiration values higher than the set-point were decreased toward the set-point with increasing BT concentrations while LCLs with ATP-linked respiration values lower than the set-point were increased toward the set-point.
increased toward the set-point with increasing BT concentrations. This effect appears to occur on a continuum such that higher concentrations of BT (0.7–1.0 mM) had the most profound effect.

The effect of BT on proton leak respiration was found to be curvilinear with the intercept different across LCL groups because the CNT intercept was lower than the AD-N (p < 0.001) and AD-A (p < 0.01) intercepts. Individual baseline proton leak respiration influenced the effect of BT on proton leak respiration (Fig. 6). BT reduced proton leak respiration with this effect more marked for LCLs with a higher baseline proton leak respiration. This effect occurred on a continuum such that medium concentrations of BT (0.5 mM to 0.7 mM) had the most profound effect with higher BT concentrations resulting in an increase in proton leak respiration variation.

The effect of BT on maximal respiratory capacity was found to be curvilinear with the curve of the AD-A group significantly different as compared to the CNT (p < 0.0005) and AD-N (p < 0.005) groups (Fig. 6). BT regulated maximal respiratory capacity for CNT and AD-N groups such that maximal respiratory capacity was modulated to a particular set-point as BT concentration increased. LCLs with baseline maximal respiratory capacity higher than the set-point decreased toward the set-point with increasing BT concentration while LCLs with maximal respiratory capacity lower than the set-point increased toward the set-point with increasing BT concentration. For the CNT and AD-N groups this effect occurred on a continuum with moderate concentrations of BT (0.4 mM to 0.6 mM) having the optimal effect and higher concentrations (>0.6 mM) resulting an overall decrease in maximal respiratory capacity. For the AD-A group, the effect of BT is slightly different than the other groups. Although BT regulates maximal respiratory capacity to a set-point, this occurs at higher BT concentrations (0.8 mM) with the set-point being overall higher. This explains the mean data in Fig. 4 as the maximal respiratory capacity for AD-A LCLs is maintained at a higher value while the maximal respiratory capacity for CNT and AD-N groups is decreased.

Fig. 4 Butyrate (BT) enhances the mitochondrial function in autistic lymphoblastoid cell lines (LCLs) with atypical mitochondrial function (AD-A) over and above the effect it has on control LCLs in a concentration- and exposure time-dependent manner. ATP-linked respiration (a), maximal respiratory capacity (c), and reserve capacity (d) were enhanced over and above the control values for the AD-A LCLs with BT exposure, particularly for 0.1 and 1.0 mM BT concentrations. The bars adjacent to the data lines represent overall significant differences. The color of the stars and bars represents the specific comparisons. Green represents the difference between AD-A and control LCLs. Orange represents the difference between AD-N and control LCLs. Blue represents the difference between the AD-N and AD-A LCLs. Statistical significance levels: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
Fig. 5 Butyrate (BT) enhances the parameters of ATP production even when the ASD lymphoblastoid cell lines (LCLs) are subjected to increased oxidative stress, especially for the ASD LCLs with atypical mitochondrial function (AD-A). LCLs are pretreated with 10 µM of 2,3-dimethoxy-1,4-naphthoquinone (DMNQ) for 1 h to increase the intracellular reactive oxygen species before the mitochondrial assay after BT has been washed from the cell culture. BT significantly increased the maximal respiratory capacity (c) above the control values in a manner similar to the increase seen without DMNQ exposure. This positively affected the reserve capacity (d). The color of the stars and bars represents the specific comparisons. Green represents the difference between AD-A and control LCLs. Orange represents the difference between AD-N and control LCLs. Blue represents the difference between the AD-N and AD-A LCLs. Statistical significance levels: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001

Fig. 6 The effect of butyrate on the individual variation in mitochondrial function for the three types of lymphoblastoid cell lines.
capacity for the CNT LCLs was lower at higher BT concentrations.

The effect of BT on reserve capacity was found to be curvilinear with the curve of the AD-A group significantly different as compared to the CNT (p < 0.001) and AD-N (p = 0.001) groups. Baseline reserve capacity influenced the effect of BT on reserve capacity with this effect significantly different in the AD-A group as compared to the CNT (p < 0.001) and AD-N (p = 0.001) groups (Fig. 6).

For CNT and AD-N LCLs, reserve capacity was modulated by BT concentration to a particular set-point despite the reserve capacity baseline. LCLs with baseline reserve capacity higher than the set-point decreased toward the set-point with increasing BT concentration while LCLs with reserve capacity lower than the set-point increased toward the set-point as BT concentration increased. This effect occurred on a continuum with moderate concentrations of BT (~0.6 mM) having the optimal effect and higher BT concentrations (>0.6 mM) resulting in a lower in reserve capacity for CNT LCLs and a more variable reserve capacity for the AD-N LCLs. For the AD-A LCLs, BT regulated reserve capacity to an overall higher set-point at higher BT concentration (~0.9 mM). This explains the mean data in Fig. 4 where the reserve capacity for AD-A LCLs is maintained at a higher value while the reserve capacity for the CNT LCLs was lower at higher BT concentrations.

Gene expression studies: BT alters the expression of mitochondrial genes

We determined whether 0.1 mM and 1.0 mM BT altered gene expression as compared to baseline (0 mM BT) across the three LCL groups (CNT, AD-N, AD-A). Overall we found no LCL groups by BT concentration interaction, but did find differences in gene expression as a result of BT concentration and across LCL groups separately (see Table S4 for statistical values). BT significantly increased the expression of many genes at 1 mM, but not at 0.1 mM (Fig. 7).

BT resulted in an increase in the expression of genes associated with mitochondrial dynamics, particularly mitochondrial fission and mitophagy (Fig. 7). Two of the three mitochondrial fission genes (DRP1, FIS1) showed a significant increase. All of the three mitophagy genes showed a significant increase, specifically PINK1, LC3, and PTEN. Only one of the two fusion genes, specifically MFN2, demonstrated a modest increase. The one apoptosis gene studied (BNIP3) did not significantly increase in expression. Three of the four genes associated with response to oxidative stress increased expression, specifically UCP2, NRF2, and SOD2. Three of the four genes associated with energy metabolism increased expression, specifically mTOR, AMPK, and SIRT3. The two genes associated with physiological stress demonstrated significant upregulation, specifically PGC1α and HIF1α. In addition, the pathways associated with the regulation of behavior and cognition were also upregulated, including Cam Kinase II and CREB1.

Several differences in gene expression were found between LCL groups independent of the BT concentration. AD-N demonstrated significantly greater expression than CNT in several genes including Cam Kinase II (p = 0.01), DRP1 (p < 0.01), MFN2 (p < 0.01), mTOR (p < 0.05), and OPA1 (p < 0.01). AD-A LCLs demonstrated significantly greater expression than CNT in several genes including CREB (p < 0.01) and DRP1 (p = 0.01). Additionally, as compared to AD-A, AD-N LCLs showed lower expression of HIF1α (p = 0.01) and higher expression of SIRT1 (p < 0.05).

Discussion

This is the first systematic investigation of the effects of BT on mitochondrial function in LCLs as well as the first study to demonstrate the effect of BT on mitochondria in tissues from individuals with ASD. In this study, we examined the effect of BT on mitochondrial function in transformed B-cells (i.e., LCLs) derived from children with ASD with and without a unique type of mitochondrial dysfunction as well as LCLs from typically developing age-matched boys. Further to both the positive and negative effects of SCFAs including BT in various conditions, it was hypothesized that several factors such as BT concentration, exposure time, microenvironment redox state, and cell type would alter the manner in which BT is metabolized and utilized. Thus, these parameters were systematically altered to gain an insight into the effects of BT on mitochondrial function.

Although the measurements of SCFA concentrations are technically difficult, it should be noted that the BT concentrations selected were physiologically relevant. The highest concentration of BT, equivalent to 1000 μM BT, is consistent with inter-enteric concentration in the colon but much higher than the systemic concentrations. The lowest concentration of BT, which is equivalent to 100 μM, is closer to blood concentrations in the portal vein. Portal vein concentrations are about twice the hepatic vein concentrations due to the metabolism of BT in the liver, and peripheral blood concentrations are about one-third the hepatic vein concentrations. Thus, under normal circumstances, the highest level of BT we examined are only relevant to enteric physiology in healthy individuals, although disruptions of the microbiome could increase these levels beyond the typical concentration during dysbiotic states. However, BT may act locally to alter GI physiology and/or the gut-associated lymphoid tissue (GALT) function, which may, in turn, affect host physiology. Below we summarize our findings as well as
Fig. 7  Change in expression of key genes involved in the response to physiological stress as a result of butyrate exposure
discuss the potential importance of BT in health and disease.

**The effect of BT on control cell lines**

BT demonstrated a concentration-dependent effect on CNT LCLs such that the highest BT concentration influenced mitochondrial function with this effect independent of the exposure time. One millimolar BT decreased the respiratory parameters linked to ATP production, including ATP-linked respiration, maximal respiratory capacity, and reserve capacity, but did not have any effect on the regulation of ROS at the inner mitochondrial membrane. BT decreased glycolysis in the control LCLs, with a greater decrease in glycolytic metabolism as compared to oxidative metabolism, resulting in an increase in the oxidative to glycolytic ratios.

Increasing ROS reversed this detrimental effect of BT on respiratory parameters in CNT LCLs, actually increasing ATP-linked respiration at 0.1 mM BT and increasing reserve capacity at 1.0 mM BT in the presence of ROS. Interestingly, BT had a more complex effect on glycolytic pathways, reducing glycolytic rate but increasing glycolytic reserve. This resulted in a complex change in the relative oxidative to glycolytic pathways, resulting in a relative increase in the basal ongoing oxidative respiration but a decrease in the relative maximal oxidative respiration.

The analysis of individual LCLs provides some insight into the effect of oxidative stress on the mitochondria in the CNT LCLs. Indeed, in the individual LCL analysis, BT was found to modulate the mitochondrial function toward a set-point unique to the LCL group such that high values are brought down toward the set-point and low values are brought up to the set-point. Thus, this suggests that BT may help optimize the mitochondrial function specific to the physiology of the particular cell. This highlights the positive effect of BT on cells under physiological stress. The potential mechanisms are discussed below.

**The effect of BT on LCLs derived from children with ASD**

For AD-A LCLs, BT increased the respiratory parameters related to ATP production, including ATP-linked respiration, maximal respiratory capacity, and reserve capacity, as compared to baseline. This effect was not seen for the AD-N LCLs. This effect of increasing the respiratory parameters cannot be simply interpreted as positive or negative, but the DMNQ challenge which increased the intracellular oxidative stress can help put these findings into context.

AD-A LCLs at baseline are found to have increases in respiratory parameters related to ATP production. Although we believe that this is an adaptation to protect the cell and might make AD-A LCLs more resistant to toxicants\(^{64}\), in our previous studies, we found that the AD-A LCLs are more sensitive to acute increases in ROS. Indeed, in other studies, without BT exposure, challenge with DMNQ to acutely increase ROS results in a significant decrease in respiratory parameters related to ATP production in AD-A LCLs as compared to control and AD-N LCLs\(^{80,81,83}\). However, in this study, when AD-A LCLs were exposed to BT for 24 or 48 h, treatment with DMNQ to increase ROS increased the respiratory parameters linked to ATP production to an equal amount or, in many cases, a higher amount than the control LCLs. This is consistent with our recent study where we demonstrated that treatment with DMNQ after prolonged exposure to a toxicant enhanced the respiratory parameters related to ATP production in AD-A but not AD-N LCLs\(^{83}\). This effect was believed to occur due to the recruitment of mitoplasticity pathways, resulting in the upregulation of genes to improve mitochondrial function during times of physiological stress such as the ones identified to be upregulated in this study.

AD-N LCLs, which do not show mitochondrial dysfunction at baseline, were not significantly influenced by BT except when ROS was increased, in which case reserve capacity was significantly elevated at 0.1 mM BT. This again suggests that BT has a modulatory effect on the mitochondria by recruiting pathways involved in enhancing mitochondrial function to protect the cell from physiological stressors.

**Effects of BT on mitochondrial protective pathways**

BT has been shown to have positive health effects by stimulating mitochondrial function. In high fat diet-induced obese mice, BT enhanced the mitochondrial oxidative phosphorylation and upregulated the expression of fatty acid oxidation enzymes and uncoupling proteins (UCP)\(^{69}\) and induced nuclear-encoded mitochondrial genes, including peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC1\(\alpha\)), resulting in mitochondrial adaptations that result in more complete \(\beta\)-oxidation and improved insulin sensitivity\(^{70,71}\). Many of these changes occur as part of a process known as mitoplasticity, which refers to the mitochondria’s ability to adapt in order to optimally function in the face of changes in energy demand, substrate availability, pathophysiology, or environmental stressors\(^{91}\). Mitoplasticity involves pathways that modulate general cellular energetics, mitochondrial enzymes in the citric acid cycle (CAC) and electron transport chain (ETC), proton leak, redox regulation, and transcription factors as well as genes that regulate the control of mitochondrial repair and regeneration such as mitochondrial biogenesis, mitophagy, and mitochondrial fission and fusion\(^{71}\). Many of these mitoplastic processes may occur through PGC1\(\alpha\) as PGC1\(\alpha\) upregulates genes important for mitochondrial metabolism, including nuclear respiratory factors (NRF-1, NRF-
mitochondrial function has been shown in other cell types. Interestingly, this same pattern of modulation of metabolism (mTOR, AMPK, SIRT3). Our study demonstrates that the increases in expression of these genes occurs at 1.0 mM BT but not at lower BT concentrations. At this concentration, BT increased the oxygen consumption and attenuated glycolysis, particularly in the AD-A LCLs. Interestingly, this same pattern of modulation of mitochondrial function has been shown in other cell types which exhibit mitochondrial dysfunction, specifically breast cancer cells where BT has an anti-cancer effect.

Proton leak respiration represents a mechanism to compensate for increased ROS at the inner mitochondrial membrane, which is mediated by UCP2 in lymphocytes. UCP2 is known to be upregulated in the context of prolonged oxidative stress and serves to protect the mitochondria. We have shown that UCP2 is increased in the AD-A LCLs as compared to AD-N LCLs. Interestingly, BT has been shown to reduce mitochondrial ROS by increasing proton leak through upregulation of UCP2. We have shown that upregulation of UCP2 is an important mechanism for regulating ROS in AD-A LCLs in previous studies, in ASD siblings with biomarkers of increased ROS, and have now demonstrated that BT further increases the gene expression of UCP2 in all LCLs regardless of the type in this study, so BT may be enhancing this compensatory mechanism in the AD-A LCLs.

In cell lines other than LCLs, BT also seems to positively modulate the mitochondrial integrity. For example, BT improved the survival of Chinese hamster ovary cells by recruitment of a mitophagy protein, Parkin, along with inducing autophagic removal of damaged mitochondria. In our study, we found that the genes associated with mitophagy and recruitment of genes involved in pathways which typically compensate for physiological stress, such as DRP1, are upregulated with increased BT concentrations.

**Effects of BT on genes involved in the regulation of learning, memory, and behavior**

In this study, we show that BT increases the expression of genes involved in behavior and learning, specifically CREB and CamKinase II. Such findings are consistent with our previous studies, which showed enhanced CREB and phospho-CREB immunoreactivity in brains from rats centrally infused with PPA, and similar findings with PPA and BT exposure in CREB-associated pathways in rat pheochromocytoma cell lines. Many findings relating to CREB physiology in the brain have been shown to have parallels in peripheral immune cells. This is a subject of further study. We have proposed that enteric SCFAs may provide a functional pathway for the microbiome to "enforce memory" in the host nervous system, and that over exposure of these metabolites may lead to the enhanced memory, rigid behavior, and motor symptoms associated with ASD by increasing CREB expression. CamKinase II activity has been proposed to be a mechanism associated with regulating repetitive, involuntary, and obsessive behaviors in psychiatric disease, suggesting that BT could have a potential role in modulating these ASD-associated behaviors.

**Connection with patients with autism**

There are many lines of evidence that BT may be helpful in normalizing the behavior and physiological abnormalities in ASD. In animal models of ASD, BT positively modulates neurotransmitter gene expression, and rescues the ASD-type behavior and brain pathology, induced by prenatal valproic acid exposure. Additionally, BT has been found to modulate the ASD-related genes in cell line models. BT has interesting effects on behavior and gene expression in the brain of the BTBR mouse model of ASD. BT decreased the excitatory and increased the inhibitory neurotransmitter genes in the prefrontal cortex and had a positive effect on behavior by increasing social behavior and decreasing repetitive behavior through modulating the excitatory–inhibitory balance of the brain. Interestingly, BT is helpful in other neurological disorders that have an underlying mitochondrial dysfunction as it has been shown to alleviate cognitive deficits in premotor stage Parkinson’s disease.

Thus, BT may be a promising treatment for children with ASD. Further preclinical and clinical studies will be needed to investigate this possibility.

**Connection with the enteric microbiome**

Studies point to overrepresentation of *Clostridia* spp in children with ASD, particularly children with ASD who experienced developmental regression and/or those with GI symptoms at or before ASD symptom onset. Treatment with vancomycin, an antibiotic aimed at decreasing *Clostridia* spp, transiently decreases ASD symptoms and studies have suggested that the reduction in dietary refined carbohydrates, a substrate for enteric bacteria that produce PPA, result in ASD symptom improvement. In addition, our previous studies have...
suggested that an overabundance of PPA, a SCFA produced by \textit{Clostridia} spp, could be disrupting mitochondrial function in some children with ASD\textsuperscript{37}. This suggests that \textit{Clostridia} spp, or other SCFA producing gut bacteria, could have a connection with the etiology of ASD.

However, the same bacteria which produce PPA also produce BT, the relative production of which may be dependent upon the dietary substrate. We have also shown that high intracerebroventricular infusions of BT produce hyperactivity and some lipid effects consistent with ASD, similar to that found with PPA infusions, albeit to a lesser extent\textsuperscript{109,110}. Furthermore, BT has been shown to upregulate genes for fatty acid oxidation. Interestingly, the increased acyl-carnitines seen in the PPA rat model of ASD and as well as in children with ASD suggest a reduced ability to breakdown fatty acids\textsuperscript{37}. Thus, it may be that there is an imbalance in the relative production of BT in relation to PPA or in the bacteria that preferentially produce BT, particularly at key neurodevelopmental time periods associated with the development of ASD. Furthermore, various low refined carbohydrate diets proposed to help in ASD may do so by reducing these substrates leading to reduced SCFA production by ASD-associated bacteria, while supplementation of foods higher in complex fibers (i.e., inulins) may exert a therapeutic effect by preferentially increasing BT production over PPA\textsuperscript{18}.

BT is absorbed both passively and actively and is transported by specific monocarboxylate transporters which also transport other SCFAs (i.e., propionate) and ketones\textsuperscript{111}. BT also activates specific free fatty acid G protein-coupled receptors\textsuperscript{12}. However, BT is also a mitochondrial fuel that is directly integrated into energy metabolism through the production of Acetyl-CoA, the first metabolite of the CAC. In fact, germ-free mice demonstrate a specific deficit in bioenergetics in colon tissue with this deficiency rescued by the BT-producing bacteria \textit{Butyrvibrio fibrisolvens}. Further experiments have suggested that this effect was a consequence of BT being used as a mitochondrial fuel rather than its effect as a histone deacetylase inhibitor\textsuperscript{40}.

**Limitations**

It should be noted that the findings in this study may or may not relate to other tissue types (i.e., brain, colon), doses, or critical time periods in development. Additionally, BT has other indirect effects, including the activation of broad signaling pathways such as those that are induced by free fatty acid G protein-coupled receptors activation, which can exert complex effects on immunity, mitochondrial function, and gene expression independent of the direct effects of BT on mitochondrial function and gene expression noted here. We do not know if these effects are independent, reinforcing, mutually exclusive, or compensatory. These are a subject of further inquiry.

Human studies, particularly clinical trials, will be most helpful in further understanding if BT is therapeutic for human disease. Indeed, although we have generally interpreted the results to demonstrate a positive effect of BT on physiology, biological organisms are complex, so the theoretical interpretation of the data may not be a direct application to complex intact physiological systems. Additionally, some of the alterations in gene function may not be beneficial in all populations. For example, individuals with Tuberous Sclerosis, a disorder characterized by uncontrolled upregulation of mTOR, would worsen with further upregulation of mTOR.

Nonetheless, these findings are consistent with the effects of BT and other SCFA and microbiome metabolites, such as PPA, as having potential to broadly modulate host physiology and behavior in both health and disease, in particular ASD.

**Conclusion**

BT is an SCFA derived from the enteric microbiome which is a mitochondrial fuel and modulator of mitochondrial function and gene expression. In this study, we demonstrated, for the first time, that BT has a modulatory effect on mitochondrial function in LCLs from both healthy children and children with ASD. What is most significant about our study is that we found that BT has a positive effect on a cell line under physiological stress, including cell lines with baseline normal mitochondrial function that are induced to have mitochondrial dysfunction through inducing physiological stress and, in particular, cell lines with underlying mitochondrial dysfunction (i.e., AD-A). This ability to rescue cells under physiological stress may provide insight into the therapeutic effect of BT in many disease states and may suggest that BT may be a novel therapeutic agent that may have implications for many diseases associated with mitochondrial dysfunction as well as patients with mitochondrial disease.

Further research will be needed to extend these findings to other cell types (i.e., neurons, glia, liver, gut) and other disease states. Nonetheless, this study provides a new understanding of how the enteric microbiome may modulate host physiology at a variety of levels and may contribute to the etiology and possible treatment of ASD and other diseases.

**Acknowledgements**

We thank the autism families that participated in the Autism Genetic Research Exchange and the studies at the National Institutes of Mental Health. We would also like to express our utmost thanks to David Patchell-Evans, for his tireless devotion to persons with autism, and his daughter, Kilee Patchell-Evans. Our heartfelt thanks go out to countless parents and caregivers of persons with autism who have shared their stories. This research was supported by the
References

1. Rosenfeld, C. S. Microbiome disturbances and autism spectrum disorders. Drug Metab. Dispos. 43, 1557–1571 (2015).
2. Frye, R. E. et al. Approaches to studying and manipulating the enteric microbiome to improve autism symptoms. Microb. Ecol. Health Dis. 26, 26878 (2015).
3. Tumbaugh, P. J. & Gordon, J. I. The core gut microbiome, energy balance and obesity. J. Physiol. 587, 4153–4158 (2009).
4. Naviaux, R. K. Metabolic features of the cell danger response. Mitochondrion 16, 7–17 (2014).
5. Johnson, C. C. & Ownby, D. R. Allergies and asthma: do atopic disorders result from inadequate immune homeostasis arising from infant gut dysbiosis? Expert. Rev. Clin. Immunol. 12, 379–388 (2016).
6. Nicholson, J. K. et al. Host-gut microbiota metabolic interactions. Science 336, 1262–1267 (2012).
7. Mackerron, A. E. & Milligan, G. The emerging pharmacology and function of GPR35 in the nervous system. Neuropharmacology 113, 661–671 (2017).
8. Cureau, N., Alahdali, N., Vo, N. & Carbonero, F. Epigenetic mechanisms in microbial members of the human microbiota current knowledge and perspectives. Epigenomics 8, 1209–1273 (2016).
9. Woot, V. & Alenghat, T. Host-microbiota interactions: epigenomic regulation. Curr. Opin. Immunol. 44, 52–60 (2017).
10. Bore, Y. E., Moloney, R. D., Clarke, G., Dinan, T. G. & Cryan, J. F. The impact of microbiota on brain and behavior: mechanisms & therapeutic potential. Adv. Exp. Med. Biol. 817, 373–403 (2014).
11. Bull, M. J. & Pummer, N. T. Part 2. Treatments for chronic gastrointestinal disease and gut dysbiosis. Integ. Med. 14, 25–33 (2015).
12. Gollwitzer, E. S. & Marland, B. J. Microbiota abnormalities in inflammatory airway diseases - potential for therapy. Pharmacol. Ther. 141, 32–39 (2014).
13. Palacios, I. et al. The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: study protocol for a randomized controlled trial. Trials 18, 7 (2017).
14. Paun, A., Yau, C. & Danska, J. S. The influence of the microbiome on type 1 diabetes. J. Immunol. 198, 590–595 (2017).
15. Wegielka, I. & Suliburska, J. The role of intestinal microbiota in the pathogenesis of metabolic diseases. Acta Sci. Pol. Technol. Aliment. 15, 201–211 (2016).
16. Bischoff, S. C. et al. Towards a multidisciplinary approach to understand and manage obesity and related diseases. Clin. Nutr. 36, 917–938 (2017).
17. Fandirks, L. Roles of the gut in the metabolic syndrome: an overview. J. Intern. Med. 281, 319–336 (2017).
18. Bourassa, M. W., Alim, L., Bultman, S. J. & Ratan, R. R. Butyrate, neuroepigenetics and the gut microbiome. Can a high fiber diet improve brain health? Neurosci. Lett. 625, 56–63 (2016).
19. Diaz Hejtz, R. et al. Normal gut microbiota modulates brain development and behavior. Proc. Natl. Acad. Sci. USA 108, 3047–3052 (2011).
20. Slattery, J., MacFabe, D. F. & Frye, R. E. The significance of the enteric microbiome on the development of childhood disease: a review of prebiotic and probiotic therapies in disorders of childhood. Clin. Med. Insights Pediatr. 10, 91–107 (2016).
21. Slattery, J., MacFabe, D. F., Kahler, S. G. & Frye, R. E. Enteric ecosystem disruption in autism spectrum disorder can the microbiota and macrobiota be restored? Curr. Pharm. Des. 22, 6107–6121 (2016).
22. Hersoug, L. G., Moller, P. & Loft, S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes. Rev. 17, 297–312 (2016).
23. Dworak, J. The medium is the message: interspecies and interkingdom signaling by peptidoglycan and related bacterial glycans. Annu. Rev. Microbiol. 68, 137–154 (2014).
24. Pimentel, M., Mathur, R. & Chang, C. Gas and the microbiome. Curr. Gastroenterol. Rep. 15, 356–366 (2013).
25. MacFabe, D. Autism: metabolism, mitochondria, and the microbiome. Glob. Adv. Health Med. 2, 52–66 (2013).
26. MacFabe, D. F. Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microb. Ecol. Health Dis. 23 (2012). http://dx.doi.org/10.3402/mehd.v23i0.19260.
27. Al-Lahham, S. H., Peppelenbosch, M. P., Roelofsen, H., Vonk, R. J. & Venema, K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochem. Biophys. Acta 1801, 1175–1183 (2010).
28. den Besten, G. et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325–2340 (2013).
29. Nakao, S., Motiya, Y., Furuyama, S., Niederman, R. & Sugaya, H. Propionic acid stimulates superoxide generation in human neutrophils. Curr. Biol. 22, 331–337 (1998).
30. Han, J. H. et al. The effects of propionate and valerate on insulin responsiveness for glucose uptake in 3T3-L1 adipocytes and C2C12 myotubes via G protein-coupled receptor 41. PLoS ONE 9, e95268 (2014).
31. Rorig, B., Klausa, G. & Sutor, B. Intracellular acidification reduced gap junction coupling between immature rat neocortical pyramidal neurones. J. Physiol. 490, 31–49 (1996).
32. Nguyen, N. H. et al. Propionite increases neuronal histone acetylation, but is metabolized oxidatively by g1a. Relevance for propionic academia. J. Neurol. 201, 806–814 (2007).
33. Nankova, B. B., Agarwal, R., MacFabe, D. F. & LaGamma, E. F. Enteric bacterial metabolites propionic and butyric acid modulate gene expression, including CREB-dependent catecholaminergic neurotransmission, in PC12 cells–possible relevance to autism spectrum disorders. PLoS ONE 9, e105740 (2014).
34. Le Poul, E. et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278, 25481–25489 (2003).
35. De Castro, M. et al. Short chain fatty acids regulate tyrosine hydroxylase gene expression through a cAMP-dependent signaling pathway. Brain Res. 112, 28–38 (2005).
36. Frye, R. E., Rose, S., Slattery, J. L. & MacFabe, D. F. Gastrointestinal dysfunction in autism spectrum disorder: the role of the mitochondria and the enteric microbiome. Microb. Ecol. Health Dis. 26, 27458 (2015).
37. Frye, R. E., Meinyk, S. & MacFabe, D. F. Unique acylcarnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder. Transl. Psychiatry 3, e220 (2013).
38. Al-Lahham, S. et al. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. Eur. J. Clin. Investig. 42, 357–364 (2012).
39. Lewson, M. E. Effect of colony flora and short-chain fatty acids on growth in vitro of Pseudomonas aeruginosa and Enterobacteriaceae. Infect. Immun. 8, 30–35 (1973).
40. Donohoe, D. R. et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell. Metab. 13, 517–526 (2011).
41. Rane, P. et al. The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology 62, 2409–2412 (2012).

42. Stillings, R. M. et al. The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis? Neurochem. Int. 99, 110–132 (2016).

43. Brown, C. T. et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE 6, e25792 (2011).

44. Patterson, E. et al. Streptozotocin-induced type-1 diabetes disease onset in Sprague-Dawley rats is associated with an altered intestinal microbiota composition and decreased diversity. Microbiol. 161, 182–193 (2015).

45. Butchbach, M. E. et al. Protective effects of butyrate-based compounds on a cerebral tumor model. Front. Cell. Neurosci. 11, 82 (2017).

46. Rose, S. et al. Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines in a well-matched case control cohort. PLoS ONE 9, e85436 (2014).

47. Kurita-Ochiai, T. & Ochiai, K. Butyric acid induces apoptosis via oxidative stress and mitochondrial dysfunction in the skeletal muscle of mice. Oxid. Med. Cell. Long. 2017, 1–14 (2017).

48. Williams, B. L. et al. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. PLoS ONE 6, e24585 (2011).

49. Finoglio, S. M. et al. Gastrointestinal microflora studies in late-onset autism. Clin. Infect. Dis. 35, 56–516 (2002).

50. Maebae, D. F. Enteric short-chain fatty acids: microbial messengers of metabolism, gut-brain, and mind: implications in autism spectrum disorders. Microb. Ecol. Health Dis. 26, 28177 (2015).

51. Foley, K. A., MacFabe, D. F., Kavaliers, M. & Ossenkopp, K. P. Sexually dimorphic effects of prenatal exposure to lipopolysaccharide, and prenatal and post-natal exposure to proprionic acid, on acoustic startle response and prepulse inhibition to adolescent rats: relevance to autism spectrum disorders. Behav. Brain Res. 278, 244–256 (2015).

52. Foley, K. A., MacFabe, D. F., Vaz, A., Ossenkopp, K. P. & Kavaliers, M. Sexually dimorphic effects of prenatal exposure to propionic acid and lipopolysaccharide on social behavior in neonatal, adolescent, and adult rats: implications for autism spectrum disorders. Int. J. Dev. Neuros. 39, 68–74 (2018).

53. Foley, K. A., Ossenkopp, K. P., Kavaliers, M. & MacFabe, D. F. Pre- and neonatal exposure to lipopolysaccharide or the enteric metabolites, propionic acid, alters development and behavior in adolescent rats in a sexually dimorphic manner. PLoS ONE 9, e80702 (2014).

54. Frey, R. E. Biomarkers of Abnormal Energy Metabolism in Children with Autism Spectrum Disorder. North Am. J. Med. Sci. 5, 141–147 (2012).

55. Frey, R. E. et al. Modulation of mitochondrial function by the microbiome metabolite propionic acid in autism and control cell lines. Transl. Psychiatry 6, e927 (2016).

56. Karuma, K. et al. Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dentate spine loss in a mouse model of autism. Pharmacol. Biochem. Behav. 126, 43–49 (2014).

57. Katsman, N., Getserel, D. & Elliott, S. Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model. Neuropharmacology 102, 136–145 (2016).

58. Kim, J. W. et al. Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism. PLoS ONE 9, e104927 (2014).

59. Hong, J. et al. Butyrate alleviates high fat diet-induced obesity through activation of adiponectin-mediated pathway and stimulation of mitochondrial function in the skeletal muscle of mice. Oxctarget 7, 56071–56082 (2016).

60. Henanigari, T. M. et al. Sodium butyrate epigenetically modulates high-fat diet-induced skeletal muscle mitochondrial adaptation, obesity and insulin resistance through nucleosome positioning. Br. J. Pharmacol. 172, 2782–2798 (2015).

61. Gay, Z. et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509–1517 (2009).

62. Sun, J. et al. Antidepressant-like effects of sodium butyrate and its possible mechanisms of action in mice exposed to chronic unpredictable mild stress. Neurosci. Lett. 618, 159–166 (2016).

63. Ferrante, R. J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. J. Neurosci. 23, 9418–9427 (2003).

64. Govindarajan, N., Agis-Balboa, R. C., Walter, J., Sananbenesi, F. & Fischer, A. Sodium butyrate improves memory function in an Alzheimer’s disease mouse model when administered at an advanced stage of disease progression. J. Alzheimer’s Dis. 26, 187–197 (2011).

65. Sharma, B. & Singh, N. Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. PLoS ONE 7, e49681 (2012).

66. Oka, Y. et al. Butyrate improves memory function in an Alzheimer’s disease mice. J. Neurosci. 23, 5286–5291 (2003).

67. Pellizzaro, C., Coradini, D. & Daidone, M. G. Modulation of angiogenesis-s per family in autism spectrum disorder to achieve optimal outcomes. Brain Res. 1420, 122–130 (2011).

68. Chang, J. G. et al. Treatment of skin diseases with short chain fatty acids. Proc. Natl. Acad. Sci. USA 98, 9086–9813 (2001).

69. Naldsug, M. et al. Short chain fatty acids induce colonic mucosal injury in rats with various postnatal ages. Pediatr. Res. 57, 201–204 (2005).

70. Rose, S. et al. Evaluation of oxidative stress and inflammation associated with low glutathione redox status in the autism brain. Transl. Psychiatry 2, e134 (2012).

71. Rose, S. et al. Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines in a well-matched case control cohort. PLoS ONE 9, e85436 (2014).

72. Rose, S. et al. Mitochondrial and redox abnormalities in autism lymphoblastoid cells: a sibling control study. FASEB J. 31, 904–909 (2017).

73. Rose, S., Wynne, R., Frey, R. E., Melnyk, S. & James, S. J. Increased susceptibility to ethylmercury-induced mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines. J. Toxicol. 2015, 573701 (2015).

74. Rose, S. et al. Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines. Transl. Psychiatry 4, e837 (2014).

75. Frey, R. E. et al. Oxidative stress challenge uncovers trichloroacetate/ketohydrate hydrate-induced mitophagy in autist and control lymphoblastoid cell lines. Sci. Rep. 7, 4478 (2017).

76. Pellizzaro, C., Coradini, D. & Daidone, M. G. Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29 Carcinogenesis 23, 735–740 (2002).

77. Coradini, D., Pellizzaro, C., Marcelini, D., Abolafio, G. & Daidone, M. G. Sodium butyrate modulates cell cycle-related proteins in HT29 human colorectal carcinoma cells. Cell. Prolif. 33, 139–146 (2000).

78. Cunningham, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P. & Maclarine, G. T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221–1227 (1987).

79. Karuri, A. R., Dobrowsky, E. & Tannock, L. F. Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment. Br. J. Cancer 68, 1080–1087 (1993).
89. Frye, R. E. et al. Objective phonological and subjective perceptual characteristics of syllables modulate spatiotemporal patterns of superior temporal gyrus activity. *Neuropsychologia* **40**, 1888–1901 (2008).

90. Cuenco, M. E. & Ochiai, K. Re-discovering periodontal butyric acid: New insights on an old metabolite. *Microb. Pathog.* **94**, 48–53 (2016).

91. Jose, C., Metser, S., Bernard, G. & Rossignol, R. Mitoplasticity: adaptation biology of the mitochondrion to the cellular redox state in physiology and carcinogenesis. *Antioxid. Redox Signal.* **18**, 838–849 (2013).

92. Jiang, Y., Chen, J., Tong, J. & Chen, T. Trichloroethylene-induced gene expression and DNA methylation changes in B6C3F1 mouse liver. *PLoS ONE* **9**, e16179 (2014).

93. Kang, C. & Li, L. Role of PGC-1alpha signaling in skeletal muscle health and disease. *Ann. NY Acad. Sci.* **1271**, 110–117 (2012).

94. Li, L. X., Skorpen, F., Egeberg, K., Jorgensen, I. H. & Grill, V. Uncoupling protein-2 participates in cellular defense against oxidative stress in clonal beta-cells. *Biochim. Biophys. Res. Commun.* **282**, 273–277 (2001).

95. Giardina, T. M., Steer, J. H., Lo, S. Z. & Joyce, D. A. Uncoupling protein-2 accumulates rapidly in the inner mitochondrial membrane during mitochondrial reactive oxygen stress in macrophages. *Biochim. Biophys. Acta* **1777**, 118–129 (2008).

96. Davis, L. M., Rho, J. M. & Sullivan, P. G. UCP-mediated free fatty acid uncoupling of isolated cortical mitochondria from fasted animals: correlations to dietary modulations. *Epilepsy* **49**, 117–119 (2008).

97. Lee, J. S. & Lee, G. M. Effect of sodium butyrate on autophagy and apoptosis in Chinese hamster ovary cells. *Biotechnol. Prog.* **28**, 349–357 (2012).

98. Ren, X., Dvivedi, Y., Mondal, A. C. & Pandey, G. N. Cyclic-AMP response element binding protein (CREB) in the neutrophils of depressed patients. *Psychiatry Res.* **185**, 108–112 (2011).

99. Piatonik, J. et al. GSK3beta, CREB, and BDNF in peripheral blood of patients with Alzheimer’s disease and depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **50**, 83–93 (2014).

100. Cunningham, M. W. & Cox, C. J. Autocannibal resistance to dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. *Acta Physiol.* **216**, 90–100 (2016).

101. DeAngelis, M. et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. *PLoS ONE* **8**, e76993 (2013).

102. Keski, R., Gokcen, C., Bulug, U. & Terzi, Y. Investigation of the relation between anaerobic bacteria genus clostridium and late-onset autism etiology in children. *J. Immunol. Immunother.* **35**, 101–109 (2014).

103. Finegold, S. M. Therapy and epidemiology of autism–clostridial spores as key elements. *Med. Hypotheses* **70**, 508–511 (2008).

104. Parracho, H. M., Bingham, M. O., Gibson, G. R. & McCartney, A. L. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. *J. Med. Microbiol.* **54**, 987–991 (2005).

105. Song, Y., Liu, C. & Finegold, S. M. Real-time PCR quantitation of clostridia in feces of autistic children. *Appl. Environ. Microbiol.* **70**, 6459–6465 (2004).

106. Finegold, S. M., Downes, J. & Summanen, P. H. Microbiologe of regressive autism. *Anaerobe* **18**, 260–262 (2012).

107. Sandler, R. H. et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. *J. Child. Neurol.* **15**, 429–435 (2000).

108. Whiteley, P. et al. The ScarfBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. *Nutr. Neurosci.* **13**, 87–100 (2010).

109. Thomas, R. H. et al. Altered brain phospholipid and acylcarnitine profiles in propionic acid infused rodents: further development of a potential model of autism spectrum disorders. *J. Neurochem.* **113**, 515–529 (2012).

110. Thomas, R. H. et al. The enteric bacterial metabolite propionic acid alters brain and plasma phospholipid molecular species: further development of a rodent model of autism spectrum disorders. *J. Neuroinflammation* **9**, 153 (2012).

111. Conn, A. R., Fell, D. I. & Steele, R. D. Characterization of alpha-keto acid transport and beyond. *Am. J. Physiol.* **245**, E253–E260 (1983).